NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 17:43
Last Report Issued 01/19/2015 12:14

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2527B-POS
Patient ID 2527B-POS
Chain 15000134
DOB Not Given
Sex Not Given
Workorder 15000134

Received 01/19/2015

Lab ID 15000134-001
Matrix Blood
Patient Name 2527B-POS
Patient ID 2527B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2527B Lacosamide, Blood				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Lacosamide	50	mcg/mL	0.50	ELEVATED
Synonym(s): Vimpat®				

Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours.
Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively.

Mean plasma concentrations following maintenance doses:
200 mg/day: 4.99 +/- 2.51 mcg/mL;
400 mg/day: 9.35 +/- 4.22 mcg/mL;
600 mg/day: 12.46 +/- 5.60 mcg/mL.

The ratio of whole blood concentration to plasma concentration is 1.1.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.